Researcher

Dr Adam Jacob Bryant

My Expertise

The following myeloma trials are active at Liverpool Hospital. Please contact the email below for further information and referrals.

1. A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

https://clinicaltrials.gov/study/NCT05308654

2. A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)

https://clinicaltrials.gov/study/NCT05519085

3. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)

https://clinicaltrials.gov/study/NCT05552222

4. VIBER-M: a phase 1b/II study of Venetoclax, Iberdomide and Dexamethasone for patients in first or second relapse of Multiple Myeloma with t(11;14).

https://www.allg.org.au/clinical-trials-research/current-clinical-trials/

Keywords

multiple myeloma

haematology

clinical oncology

hematopoietic stem cell transplantation

equity of access

Biography

Adam is a Senior Staff Specialist Haematologist at Liverpool Hospital in South Western Sydney. He is Chair of the region’s Myeloma and Plasma Cell Disorders Unit through which he and his colleagues are responsible for a large practice of patients with myeloma and related diseases. Adam has been the Principal Investigator of numerous myeloma clinical trials and is an active member of the Myeloma Working Party of the Australia Leukaemia and...view more

Adam is a Senior Staff Specialist Haematologist at Liverpool Hospital in South Western Sydney. He is Chair of the region’s Myeloma and Plasma Cell Disorders Unit through which he and his colleagues are responsible for a large practice of patients with myeloma and related diseases. Adam has been the Principal Investigator of numerous myeloma clinical trials and is an active member of the Myeloma Working Party of the Australia Leukaemia and Lymphoma Group (ALLG). Adam’s other specific subspecialty interest is in Stem Cell Transplantation and Cellular Therapies, having been a founding member of the SW Sydney Allogeneic BMT program which commenced in 2012.
Adam is current Treasurer and NSW Councillor of the Haematology Society of Australia and New Zealand, which is involved in advocacy and education on behalf of haematologists across the region. Closer to home, he is also the Chair of the rapidly expanding Haematology Clinical Trials Unit of South Western Sydney, an entity whose mantra is to bring new and innovative therapies to a historically under resourced and underprivileged region. He has had various other roles, in particular as the former Chair of the EviQ Haematology Reference Committee, as a journal reviewer and as a presenter and editorial contributor to Australian myeloma education through organisations including Limbic, Research Review and Myeloma Australia.